Regeneron To Acquire Decibel Therapeutics, Strengthening Gene Therapy And Hearing Loss Programs
Acquiring Company
Regeneron
Acquired Company
Decibel Therapeutics, Inc.
TarrytownMassachusettsBiotechnologyHealth CareScience And EngineeringTherapeuticsBiotechnologyHealth CareTherapeuticsDescription
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. (NASDAQ: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement for the acquisition of Decibel by Regeneron at a price of $4.00 per share of Decibel common stock payable in cash at closing, with an additional non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achievement of certain clinical development and regulatory milestones for Decibel’s lead investigational candidate, DB-OTO, within specified time periods. The proposed acquisition values Decibel at a total equity value of approximately $109 million based on the amount payable at closing, and a total equity value of up to approximately $213 million if the CVR milestones are achieved.
Who to call at Regeneron, and when
When Regeneron changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Regeneron raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Regeneron, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Regeneron. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Regeneron makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Decibel Therapeutics, Inc.?
Decibel Therapeutics, Inc. was acquired by Regeneron, based in Tarrytown. The deal was reported on August 9, 2023. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Regeneron is publicly traded (REGN) and operates in Biotechnology.
When did Regeneron acquire Decibel Therapeutics, Inc.?
Regeneron's acquisition of Decibel Therapeutics, Inc. was reported on August 9, 2023. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Decibel Therapeutics, Inc. do?
Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. It is privately held, operating in Biotechnology, and is based in Massachusetts.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.